Payment overview · 2025
General Payments
$1,513.54
103 reported records · 14 companies
Healthcare provider profile · identity verified
Rickey D Manning, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1831126812
Verified facts
What the public records show
CMS Open Payments records show Rickey D Manning, MD received $1,513.54 in general payments during 2025 across 103 reported records.
ABBVIE INC. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $294.47 | 19.5% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $281.77 | 18.6% | 18 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $204.61 | 13.5% | 27 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $178.75 | 11.8% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $121.33 | 8.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.96 | 6.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.43 | 6.6% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $85.90 | 5.7% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.82 | 2.2% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $29.94 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.60 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.38 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $17.73 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.85 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,513.54 | 103 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $205.86 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $204.61 | 27 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $204.61 | 27 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $198.43 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $121.33 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $120.44 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $109.73 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $109.73 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $93.80 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.80 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $85.90 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.43 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.08 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.08 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.71 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $43.08 | 4 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $29.94 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $12.60 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $12.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 151 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 120 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
120 | 87 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1085 | 277 |
| Atorvastatin Calcium | Atorvastatin Calcium | 596 | 154 |
| Alprazolam | Alprazolam | 500 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 384 | 123 |
| Omeprazole | Omeprazole | 382 | 104 |
| Losartan Potassium | Losartan Potassium | 354 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 353 | 94 |
| Glimepiride | Glimepiride | 264 | 73 |
| Furosemide | Furosemide | 261 | 73 |
| Gabapentin | Gabapentin | 259 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 233 | 68 |
| Lovastatin | Lovastatin | 231 | 65 |
| Pioglitazone Hcl | Pioglitazone Hcl | 229 | 63 |
| Lisinopril | Lisinopril | 226 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 225 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 216 | 38 |
| Ezetimibe | Ezetimibe | 197 | 56 |
| Meloxicam | Meloxicam | 196 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 70 |
| Montelukast Sodium | Montelukast Sodium | 182 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 45 |
| Sertraline Hcl | Sertraline Hcl | 168 | 46 |
| Potassium Chloride | Potassium Chloride | 162 | 51 |
| Metformin Hcl | Metformin Hcl | 160 | 51 |
| Eliquis | Apixaban | 151 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 144 | 38 |
| Ozempic | Semaglutide | 142 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 140 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 132 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 130 | 39 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 124 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 121 | 36 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 120 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 35 |
| Simvastatin | Simvastatin | 114 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 30 |
| Benazepril Hcl | Benazepril Hcl | 112 | 28 |
| Alendronate Sodium | Alendronate Sodium | 111 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 28 |
| Allopurinol | Allopurinol | 104 | 32 |
| Clonazepam | Clonazepam | 95 | 11 |
| Fenofibrate | Fenofibrate | 95 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 93 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 24 |
| Tramadol Hcl | Tramadol Hcl | 93 | 20 |
| Famotidine | Famotidine | 91 | 26 |
| Trazodone Hcl | Trazodone Hcl | 91 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 82 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 22 |
| Lorazepam | Lorazepam | 80 | 12 |
| Prednisone | Prednisone | 80 | 29 |
| Celecoxib | Celecoxib | 77 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 32 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 70 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 20 |
| Atenolol | Atenolol | 69 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 66 | 23 |
| Januvia | Sitagliptin Phosphate | 65 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 63 | 14 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Fluconazole | Fluconazole | 62 | 25 |
| Bupropion Xl | Bupropion Hcl | 61 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 25 |
| Spironolactone | Spironolactone | 55 | 18 |
| Tradjenta | Linagliptin | 55 | 12 |
| Synthroid | Levothyroxine Sodium | 54 | 12 |
| Temazepam | Temazepam | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 27 |
| Carvedilol | Carvedilol | 51 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Azithromycin | Azithromycin | 48 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 43 | 12 |
| Estradiol | Estradiol | 43 | 14 |
| Irbesartan | Irbesartan | 43 | 11 |
| Diazepam | Diazepam | 41 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Testosterone | Testosterone | 41 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 12 |
| Jardiance | Empagliflozin | 38 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Myrbetriq | Mirabegron | 36 | 11 |
| Primidone | Primidone | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Nystatin | Nystatin | 28 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | 11 |
| Sucralfate | Sucralfate | 27 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 11 |
| Colchicine | Colchicine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 16 |
| Valsartan | Valsartan | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clonidine | Clonidine | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Aplenzin | Bupropion Hbr | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,513.54 · 103 records | ABBVIE INC. | AIRSUPRA, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, BEXSERO, BREZTRI, ELIQUIS, FREESTYLE LIBRE 3, Fluad, Flucelvax, GEMTESA, JARDIANCE, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PEDIARIX, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error